Notably, despite the increase in PI3K pathway activity (Fig. 7), and the frequent mutations in PIK3CA in breast cancer, there was no further increase in the PIK3CA mutation rate in metastases vs primary lesions. This evidence concerns the gene PIK3CA and breast carcinoma.